BMX and its role in inflammation, cardiovascular disease, and cancer

International Reviews of Immunology

Volumn 31, Issue 2, 2012, Pages 166-173

  Cenni, Bruno ^a   Gutmann, Sascha ^a   Gottar Guillier, Marie ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiogenesis; Arthritis; Cancer; Inflammation; TEC kinases

Indexed keywords

ANTINEOPLASTIC AGENT; BONE MARROW KINASE ON CHROMOSOME X; BONE MARROW KINASE ON CHROMOSOME X INHIBITOR; CGI 1746; CYTOKINE; DASATINIB; INTERLEUKIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; BLADDER CANCER; CANCER STEM CELL; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL TRANSFORMATION; CYSTECTOMY; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; HEART VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; MACROPHAGE; MOLECULAR BIOLOGY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROBLAST;

ANIMALS; ARTHRITIS; CARDIOVASCULAR DISEASES; CELL LINE; HUMANS; INFLAMMATION; MICE; MODELS, MOLECULAR; NEOPLASMS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84860439454     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.663838     Document Type: Review

References (62)

1. Manning G, Whyte DB,Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298(5600):1912-1934. (Pubitemid 35425239)
2. Ortutay C,Nore BF, Vihinen M, SmithCI. Phylogeny of Tec family kinases identification of a premetazoan origin of Btk, Bmx, Itk, Tec, Txk, and the Btk regulator SH3BP5. Adv Genet. 2008;64:51-80.
3. Robinson DR,Wu YM, Lin SF.The protein tyrosine kinase family of the human genome. Oncogene. 2000;19(49):5548-5557.
4. ManoH. Tec family of protein-tyrosine kinases: an overview of their structure and function.Cytokine Growth Factor Rev. 1999;10(3-4):267-280. (Pubitemid 30041404)
5. Felices M, Falk M, Kosaka Y, Berg LJ. Tec kinases in T cell and mast cell signaling. Adv Immunol. 2007;93:145-184. (Pubitemid 46441430)
6. Koprulu AD, Ellmeier W. The role of Tec family kinases in mononuclear phagocytes. Crit Rev Immunol. 2009;29(4):317-333.
7. Chamorro M, Czar MJ, Debnath J, et al. Requirements for activation and RAFT localization of the T-lymphocyte kinase Rlk/Txk. BMC Immunol. 2001;2:3.
8. Debnath J, Chamorro M, Czar MJ, et al. rlk/TXK encodes two forms of a novel cysteine string tyrosine kinase activated by Src family kinases.Mol Cell Biol. 1999;19(2):1498-1507. (Pubitemid 29046891)
9. Weil D, Power MA, Smith SI, Li CL. Predominant expression of murine Bmx tyrosine kinase in the granulo-monocytic lineage. Blood. 1997;90(11):4332-4340. (Pubitemid 27508439)
10. Kaukonen J, Lahtinen I, Laine S, Alitalo K, Palotie A. BMX tyrosine kinase gene is expressed in granulocytes andmyeloid leukaemias. Br J Haematol. 1996;94(3):455-460. (Pubitemid 26284066)
11. Ekman N, Lymboussaki A, Vastrik I, Sarvas K, Kaipainen A, Alitalo K. Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries. Circulation. 1997;96(6):1729-1732. (Pubitemid 27400725)
12. Guo L, Guo Y, Xiao S. Expression of Etk/Bmx tyrosine kinase in intrahepatic cholangiocarcinoma. J Surg Oncol. 2008;97(5):428-432. (Pubitemid 351466386)
13. Guo L, Guo Y, Xiao S. Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NFkappaB- associated proteins in hepatocellular carcinoma. Oncology. 2007;72(5-6):410-416. (Pubitemid 351238157)
14. Dai B, Kim O, Xie Y, et al. Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res. 2006;66(16):8058-8064. (Pubitemid 44299171)
15. Bagheri-Yarmand R,Mandal M, Taludker AH, et al. Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. J Biol Chem. 2001;276(31):29403-29409.
16. Robinson D,He F, PretlowT,KungHJ. A tyrosine kinase profile of prostate carcinoma. ProcNatl Acad Sci U S A. 1996;93(12):5958-5962. (Pubitemid 26190784)
17. TomlinsonMG, Kurosaki T, Berson AE, Fujii GH, Johnston JA, Bolen JB. Reconstitution of Btk signaling by the atypical tec family tyrosine kinases Bmx and Txk. J Biol Chem. 1999;274(19):13577-13585.
18. Ellmeier W, Jung S, Sunshine MJ, et al. Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk. J ExpMed. 2000;192(11):1611-1624.
19. Tamagnone L, Lahtinen I, Mustonen T, et al. BMX, a novel nonreceptor tyrosine kinase gene of the BTK/ITK/TEC/TXK family located in chromosome Xp22.2. Oncogene. 1994;9(12):3683-3688.
20. Valiaho J, Smith CI, Vihinen M. BTKbase: themutation database for X-linked agammaglobulinemia. HumMutat. 2006;27(12):1209-1217. (Pubitemid 44749723)
21. Rajantie I, Ekman N, Iljin K, et al. Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Mol Cell Biol. 2001;21(14):4647-4655. (Pubitemid 32588247)
22. He Y, Luo Y, Tang S, et al. Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogenesis. J Clin Invest. 2006;116(9):2344-2355. (Pubitemid 44330133)
23. Zhang R, Xu Y, Ekman N, et al. Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J Biol Chem. 2003;278(51):51267-51276. (Pubitemid 38020364)
24. Chen KY, Wu CC, Chang CF, et al. Suppression of Etk/Bmx Protects against ischemic brain injury. Cell Transplant. 2011.
25. Mitchell-Jordan SA, Holopainen T, Ren S, et al. Loss of Bmx nonreceptor tyrosine kinase prevents pressure overload-induced cardiac hypertrophy. Circ Res. 2008;103(12):1359-1362.
26. BryM, Kivela R, Holopainen T, et al. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation. 2010;122(17):1725- 1733.
27. Semaan N, Alsaleh G, Gottenberg JE, Wachsmann D, Sibilia J. Etk/BMX, a Btk family tyrosine kinase, and Mal contribute to the cross-talk between MyD88 and FAK pathways. J Immunol. 2008;180(5):3485-3491.
28. Palmer CD, Mutch BE, Page TH, Horwood NJ, Foxwell BM. Bmx regulates LPS-induced IL-6 and VEGF production viamRNA stability in rheumatoid synovial fibroblasts. Biochem Biophys Res Commun. 2008;370(4):599-602.
29. Palmer CD, Mutch BE, Workman S, McDaid JP, Horwood NJ, Foxwell BM. Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFkapp}B activity. Blood. 2008;111(4):1781-1788. (Pubitemid 351451482)
30. Huesken D, Lange J, Mickanin C, et al. Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol. 2005;23(8):995-1001. (Pubitemid 41114034)
31. Mukherji M, Bell R, Supekova L, et al. Genome-wide functional analysis of human cell-cycle regulators. Proc Natl Acad Sci U S A. 2006;103(40):14819- 14824. (Pubitemid 44527812)
32. RinesDR,Gomez-FerreriaMA,ZhouY, et al.Wholegenomefunctional analysis identifiesnovelcomponents required formitotic spindle integrity in human cells. Genome Biol. 2008;9(2):R44.
33. Gottar-Guillier M, Dodeller F, Huesken D, et al. The tyrosine kinase BMX is an essential mediator of inflammatory arthritis in a kinase-independent manner. J Immunol. 2011;186(10): 6014-6023.
34. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C,Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell. 1996;87(5):811-822. (Pubitemid 26404281)
35. Ji H, Pettit A,Ohmura K, et al. Critical roles for interleukin 1 and tumor necrosis factor at in antibodyinduced arthritis. J ExpMed. 2002;196(1):77-85. (Pubitemid 34747313)
36. Monach PA, Mathis D, Benoist C. The K/BxN arthritis model. Curr Protoc Immunol. 2008;Chapter 15:Unit.
37. Dumonde DC, Glynn LE. The production of arthritis in rabbits by an immunological reaction to fibrin. Br J Exp Pathol. 1962;43:373-383.
38. Lens JW, van den BergWB, van de Putte LB. Flare-up of antigen-induced arthritis in mice after challenge with intravenous antigen: studies on the characteristics of and mechanisms involved in the reaction. Clin Exp Immunol. 1984;55(2):287-294. (Pubitemid 14223465)
39. Chen KY, Huang LM, Kung HJ, Ann DK, Shih HM. The role of tyrosine kinase Etk/Bmx in EGFinduced apoptosis of MDA-MB-468 breast cancer cells. Oncogene. 2004;23(10):1854-1862. (Pubitemid 38445411)
40. Guo L,Guo Y, Xiao S. Expression of Etk/Bmx tyrosine kinase in the tumorigenicity of nasopharyngeal epithelium and its relation with EB virus infection and the apoptosis-related protein Bcl-2. Cancer Lett. 2006;232(2):255-261. (Pubitemid 43170975)
41. Guo S, Sun F, Guo Z, et al. Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy. PLoS One. 2011;6(3):e17778.
42. Paz K, Brennan LA, IacolinaM,Doody J,Hadari YR, Zhu Z.Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation. Mol Cancer Ther. 2005;4(11):1801-1809. (Pubitemid 41685315)
43. Guryanova OA, Wu Q, Cheng L, et al. Nonreceptor tyrosine kinase BMX maintains selfrenewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell. 2011;19(4):498-511.
44. Park DM, Rich JN. Biology of glioma cancer stem cells.Mol Cells. 2009;28(1):7-12.
45. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science. 2009;324(5935):1670-1673.
46. de la Iglesia N, Puram SV, Bonni A. STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med. 2009;9(5):580-590.
47. Saharinen P, Ekman N, Sarvas K, Parker P, Alitalo K, Silvennoinen O. The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase Cdelta. Blood. 1997;90(11):4341-4353. (Pubitemid 27508440)
48. Tsai YT, Su YH, Fang SS, et al. Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation.Mol Cell Biol. 2000;20(6):2043-2054.
49. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchowč Lancet. 2001;357(9255):539-545. (Pubitemid 32173595)
50. Keibel A, Singh V, Sharma MC. Inflammation, microenvironment, and the immune system in cancer progression. Curr PharmDes. 2009;15(17):1949-1955.
51. Middendorp S, Dingjan GM, Maas A, Dahlenborg K, Hendriks RW. Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity. J Immunol. 2003;171(11):5988-5996. (Pubitemid 37467217)
52. Muckelbauer J, Sack JS, Ahmed N, et al. X-ray crystal structure of bonemarrow kinase in the x chromosome: a Tec family kinase. Chem Biol Drug Des. 2011;78(5):739-748.
53. Liao JJ. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. JMed Chem. 2007;50(3):409-424. (Pubitemid 46239775)
54. Di Paolo JA, Huang T, Balazs M, et al. Specific Btk inhibition suppresses B cell- and myeloid cellmediated arthritis. Nat Chem Biol. 2011;7(1):41-50.
55. Singh J, Petter RC, Kluge AF. Targeted covalent drugs of the kinase family. Curr Opin Chem Biol. 2010;14(4):475-480.
56. HurW,VelentzaA,Kim S, et al.Clinical stageEGFRinhibitors irreversibly alkylateBmxkinase.Bioorg Med Chem Lett. 2008;18(22):5916-5919.
57. Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat Rev Drug Discov. 2011;10(4):307-317.
58. Fowler N, Sharman JP, Smith SM, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cellmalignancies: results from a phase I study. ASH AnnualMeeting Abstracts 2010;116(21):964.
59. Staudt LM,Dunleavy K, Buggy JJ, et al.TheBruton's tyrosine kinase (Btk) inhibitor PCI-32765 modulates chronic active BCR signaling and induces tumor regression in relapsed/refractory ABCDLBCL. ASH AnnualMeeting Abstracts 2011;118(21):2716.
60. Wang L, Martin P, Blum KA, et al. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treatedmantle cell lymphoma (MCL): preliminary results of a phase II trial. ASH AnnualMeeting Abstracts 2011;118(21):442.
61. Honigberg LA, Smith AM, SirisawadM, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010;107(29):13075-13080.
62. Johnson DS,Weerapana E, Cravatt BF. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. FutureMed Chem. 2010;2(6):949-964.